ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Survivors With Gene Variant At More Risk For Heart Disease

June 25, 2010

Organ Systems Programs “Filling the Gaps” With Targeted Research

January 23, 1987

If You Were On ODAC: Experts Suggest Questions For May 10 Advisory Meeting.

March 16, 2007

VIB CIDAC contract Extended, No Gaps In CANCERGRAMS

June 15, 1984

Funding Opportunities: RFA Available: Teams For Molecular Target Assessment

November 26, 1999

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

October 31, 2014